UNLABELLED: The distribution of hypoxic cells in an in vivo tissue engineering chamber was investigated up to 28 days post-implantation. METHODS: Arteriovenous loops were constructed and placed into bi-valved polycarbonate chambers containing 2 x 10(6) rat fibroblasts in basement membrane gel (BM gel). Chambers were inserted subcutaneously in the groin of male rats and harvested at 3 (n = 6), 7 (n = 6), 14 (n = 4) or 28 (n = 4) days. Ninety minutes before harvest, pimonidazole (60 mg/kg) was injected intraperitoneally. Chamber tissue was removed, immersion fixed, paraffin embedded, sectioned and stained immunohistochemically using hypoxyprobe-1 Mab that detects reduced pimonidazole adducts forming in cells, where pO2 < 10 mmHg. RESULTS: At 3 days a fibrin clot/BM gel framework filled the chamber. Seeded fibroblasts had largely died. The majority of 3 day chambers did not demonstrate tissue growth from the AV loop nor was pimonidazole binding present in these chambers. In one chamber in which tissue growth had occurred strong pimonidazole binding was evident within the new tissue. In four out of six 7 day chambers a broader proliferative zone existed extending up to 0.4 mm (approximately) from the AV loop endothelium which demonstrated intense pimonidazole binding. The two remaining 7 day chambers displayed even greater tissue growth (leading edge > 0.7 mm from the AV loop endothelium), but very weak or no pimonidazole binding. At 14 and 28 days the fibrin/BM gel matrix was replaced by mature vascularised connective tissue that did not bind pimonidazole. CONCLUSION: Employing a tissue engineering chamber, new tissue growth extending up to 0.4 mm from the AV loop endothelium (chambers < or = 7 days) demonstrated intense pimonidazole binding and, therefore, hypoxia. Tissue growth greater than 0.5 mm from the AV loop endothelium (7-28 days chambers) did not exhibit pimonidazole binding due to a significant increase in the number of new blood vessels and was, therefore, adequately oxygenated.
UNLABELLED: The distribution of hypoxic cells in an in vivo tissue engineering chamber was investigated up to 28 days post-implantation. METHODS: Arteriovenous loops were constructed and placed into bi-valved polycarbonate chambers containing 2 x 10(6) rat fibroblasts in basement membrane gel (BM gel). Chambers were inserted subcutaneously in the groin of male rats and harvested at 3 (n = 6), 7 (n = 6), 14 (n = 4) or 28 (n = 4) days. Ninety minutes before harvest, pimonidazole (60 mg/kg) was injected intraperitoneally. Chamber tissue was removed, immersion fixed, paraffin embedded, sectioned and stained immunohistochemically using hypoxyprobe-1 Mab that detects reduced pimonidazole adducts forming in cells, where pO2 < 10 mmHg. RESULTS: At 3 days a fibrin clot/BM gel framework filled the chamber. Seeded fibroblasts had largely died. The majority of 3 day chambers did not demonstrate tissue growth from the AV loop nor was pimonidazole binding present in these chambers. In one chamber in which tissue growth had occurred strong pimonidazole binding was evident within the new tissue. In four out of six 7 day chambers a broader proliferative zone existed extending up to 0.4 mm (approximately) from the AV loop endothelium which demonstrated intense pimonidazole binding. The two remaining 7 day chambers displayed even greater tissue growth (leading edge > 0.7 mm from the AV loop endothelium), but very weak or no pimonidazole binding. At 14 and 28 days the fibrin/BM gel matrix was replaced by mature vascularised connective tissue that did not bind pimonidazole. CONCLUSION: Employing a tissue engineering chamber, new tissue growth extending up to 0.4 mm from the AV loop endothelium (chambers < or = 7 days) demonstrated intense pimonidazole binding and, therefore, hypoxia. Tissue growth greater than 0.5 mm from the AV loop endothelium (7-28 days chambers) did not exhibit pimonidazole binding due to a significant increase in the number of new blood vessels and was, therefore, adequately oxygenated.
Authors: Jürgen H Dolderer; Andreas Kehrer; Stefan M Schiller; Ulrich H Schröder; Konrad Kohler; Hans-Eberhard Schaller; Dorothea Siegel-Axel Journal: Wien Med Wochenschr Date: 2010-03
Authors: Kira Young; Barbara Conley; Diana Romero; Eric Tweedie; Christine O'Neill; Ilka Pinz; Louise Brogan; Volkhard Lindner; Lucy Liaw; Calvin P H Vary Journal: Blood Date: 2012-09-26 Impact factor: 22.113
Authors: Rafia S Al-Lamki; Wanhua Lu; Jun Wang; Jun Yang; Timothy J Sargeant; Richard Wells; Chenqu Suo; Penny Wright; Martin Goddard; Qunhua Huang; Amir H Lebastchi; George Tellides; Yingqun Huang; Wang Min; Jordan S Pober; John R Bradley Journal: Stem Cells Date: 2013-09 Impact factor: 6.277
Authors: Chi-Hsun Hsieh; Eike A Nickel; Jun-Te Hsu; Martin G Schwacha; Kirby I Bland; Irshad H Chaudry Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: Volker J Schmidt; Johannes G Hilgert; Jennifer M Covi; Nico Leibig; Johanna O Wietbrock; Andreas Arkudas; Elias Polykandriotis; Cor de Wit; Raymund E Horch; Ulrich Kneser Journal: PLoS One Date: 2015-01-30 Impact factor: 3.240
Authors: Dan Qi; Ming Wei; Shiyu Jiao; Yanting Song; Xia Wang; Guomin Xie; Joseph Taranto; Ye Liu; Yan Duan; Baoqi Yu; Huihua Li; Yatrik M Shah; Qingbo Xu; Jie Du; Frank J Gonzalez; Aijuan Qu Journal: Cell Death Dis Date: 2019-07-18 Impact factor: 8.469
Authors: Richard Wong; Roberto Donno; Christopher Y Leon-Valdivieso; Urmas Roostalu; Brian Derby; Nicola Tirelli; Jason K Wong Journal: Sci Rep Date: 2019-07-19 Impact factor: 4.379